Under the agreements, Tallac will use Selexis' proprietary Suretechnology platform to develop research cell banks to bring its immunotherapy candidates for the treatment of solid tumors to the clinic.

Tallac is developing therapeutics with the potential to activate innate and adaptive antitumor immunity. Its TRAAC platform, which delivers a potent toll-like receptor 9 agonist (T-CpG) for targeted immune activation via systemic administration, has been used to develop a pipeline of next-generation immunotherapies across multiple tumor indications.

Selexis' modular Suretechnology platform facilitates the rapid, stable, and cost-effective production of recombinant proteins and vaccines.

ALX, Tallac collaborate on novel immunotherapies
ALX Oncology Holdings and Tallac Therapeutics are joining forces to develop, manufacture, and commercialize a novel class of cancer immunotherapeutics.